Cargando…

Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma

While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2 (SCF(Skp2)) promotes proteasomal degradation of the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malek, E, Abdel-Malek, M A Y, Jagannathan, S, Vad, N, Karns, R, Jegga, A G, Broyl, A, van Duin, M, Sonneveld, P, Cottini, F, Anderson, K C, Driscoll, J J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339431/ https://www.ncbi.nlm.nih.gov/pubmed/27677741 http://dx.doi.org/10.1038/leu.2016.258

Ejemplares similares

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib
por: Jagannathan, S, et al.
Publicado: (2015)

High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib
por: Malek, Ehsan, et al.
Publicado: (2016)

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
por: Jagannathan, S, et al.
Publicado: (2015)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Phytochemical library screening reveals betulinic acid as a novel Skp2‐SCF E3 ligase inhibitor in non–small cell lung cancer
por: He, Dan‐Hua, et al.
Publicado: (2021)

Knockdown of SCF(Skp2) Function Causes Double-Parked Accumulation in the Nucleus and DNA Re-Replication in Drosophila Plasmatocytes
por: Kroeger, Paul T., et al.
Publicado: (2013)

Skp, Cullin, F-box (SCF)-Met30 and SCF-Cdc4-Mediated Proteolysis of CENP-A Prevents Mislocalization of CENP-A for Chromosomal Stability in Budding Yeast
por: Au, Wei-Chun, et al.
Publicado: (2020)

Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
por: Zheng, Zhihong, et al.
Publicado: (2018)

The SCF(Skp2) ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L)
por: Roberts, Jamie Z., et al.
Publicado: (2020)

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
por: Yue, Yanhua, et al.
Publicado: (2022)

SKP1-like protein, CrSKP1-e, interacts with pollen-specific F-box proteins and assembles into SCF-type E3 complex in ‘Wuzishatangju’ (Citrus reticulata Blanco) pollen
por: Ren, Yi, et al.
Publicado: (2020)

Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis
por: Xie, Li, et al.
Publicado: (2023)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Anti-β(2)-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy
por: Zhang, Mingjun, et al.
Publicado: (2015)

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
por: Giallongo, Cesarina, et al.
Publicado: (2020)

CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance
por: Tang, Hailong, et al.
Publicado: (2020)

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma
por: Aziz, Abdul, et al.
Publicado: (2023)

Regulation of SCF(TIR1/AFBs) E3 ligase assembly by S-nitrosylation of Arabidopsis SKP1-like1 impacts on auxin signaling
por: Iglesias, María José, et al.
Publicado: (2018)

Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells
por: Jaganathan, Sajjeev, et al.
Publicado: (2014)

Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma
por: Abdel Malek, Mohamed A.Y., et al.
Publicado: (2014)

SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis
por: Panda, Dibyendu K., et al.
Publicado: (2022)

Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases
por: Zhou, Weihua, et al.
Publicado: (2013)

The crystal structure of the Sgt1-Skp1 complex: the link between Hsp90 and both SCF E3 ubiquitin ligases and kinetochores
por: Willhoft, Oliver, et al.
Publicado: (2017)

SCF(SKP2) regulates APC/C(CDH1)-mediated degradation of CTIP to adjust DNA-end resection in G(2)-phase
por: Li, Fanghua, et al.
Publicado: (2020)

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
por: Hofman, Isabel JF, et al.
Publicado: (2016)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
por: Beksac, Meral, et al.
Publicado: (2023)

A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue
por: Wu, Ping, et al.
Publicado: (2015)

DCUN1D3 activates SCF(SKP2) ubiquitin E3 ligase activity and cell cycle progression under UV damage
por: Zhang, Shuai, et al.
Publicado: (2016)

Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation
por: Li, Xuesen, et al.
Publicado: (2019)

Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells
por: Iskandarani, Ahmad, et al.
Publicado: (2016)

Nonstructural protein P7-2 encoded by Rice black-streaked dwarf virus interacts with SKP1, a core subunit of SCF ubiquitin ligase
por: Wang, Qian, et al.
Publicado: (2013)

Oxygen-dependent regulation of E3(SCF)ubiquitin ligases and a Skp1-associated JmjD6 homolog in development of the social amoeba Dictyostelium
por: Boland, Andrew W., et al.
Publicado: (2022)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q82hac7lig0vlp5kp4us7vkfqv